Exelixis (FRA:EX9) Short Interest

View and export this data going back to 2000. Start your Free Trial

What is Exelixis Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Exelixis's Short Interest

For the Biotechnology subindustry, Exelixis's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exelixis's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Short Interest distribution charts can be found below:

* The bar in red indicates where Exelixis's Short Interest falls into.

Exelixis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

EXEL:USA 0IJO:UK EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Headlines

No Headlines